IRHYTHM TECHNOLOGIES, INC.

IRTC
Exchange NMS, Currency in USD
Loading price...

Overview

Previous Close140.18
Open156.45
Ask200.97
Bid164.11
Day's Range152.16 - 168.32
52 Week Range55.92 - 168.32
PE Ratio(TTM)--
Market Cap5.3B
Volume1.86M
Avg. Volume511.73k
12 Months Earnings-98.32M
12 Months Revenue618.59M

Performance

ABSCAGR
YTD1 Month3 Months1 Year2 Years5 Years10 Years
No results to display

Profit/Loss

PARTICULARSTTM2024202320222021
Operating Revenue618.59M591.84M492.68M410.92M322.82M
Cost of Revenue189.36M184.31M160.88M129.29M109.26M
Gross Profit429.23M407.53M331.81M281.63M213.57M
Operating Expenses538.51M522.39M445.89M368.81M313.51M
Profit after Tax (Net Income)-98.32M-113.29M-123.41M-116.16M-101.36M

Company Profile

Sector: Healthcare
Industry: Medical Devices
HQ Location: San Francisco, United States
Website: https://www.irhythmtech.com
President, CEO & Director: Mr. Quentin S. Blackford
Employees: 2,000
About Company:
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
DISCLAIMER: Stock prices are not real time and the delay can range from a few seconds to several minutes. The data displayed are solely for informational purposes, not for trading purposes or advice.